Lymphoma Patients May Become Resistant to Therapy

Researchers from Moffitt Cancer Center and Dana-Farber Cancer Institute have discovered a mechanism of drug resistance to Venetoclax (ABT-199) a BCL-2 targeting drug commonly used to treat chronic lymphocyte leukemia and acute myeloid leukemia. The findings, published in the journal Cancer Cell, suggest a possible co-treatment strategy to overcome this resistance.
The investigators created model cell lines that were resistant to Venetoclax and compared these cells to the parental cell lines that maintained drug sensitivity. They found that Venetoclax resistance was dependent on both genetic mutations and non-mutational changes. It was also discovered that during treatment with Venetoclax, rare subpopulations of cells lose a genetic amplification of chromosome 18, a trait commonly found in patients with hematologic malignancies, and can survive from drug treatment. This loss contributes to the survival of these cell populations, according to the study.
The resistant cells developed non-mutational changes involving transcriptional reprogramming as well. According to the press release, certain regions of DNA called super-enhancers became activated or deactivated in the resistant cells, leading to either a downstream loss or gain in the protein expression, which ultimately contributed to cell survival.
“The study, for the first time, unified genetic alteration and non-genetic adaptive response as a driving force for drug resistance evolution to therapy," Jianguo Tao, who led the research team, said in a press release.
The transcriptional reprogramming was dependent on a protein called CDK7. These observations suggested that targeting CDK7 may be an effective strategy to prevent Venetoclax resistance, according to the study.
The researchers conducted a chemical screening of a set of small molecule inhibitors, which further confirmed their hypothesis by showing that combination treatment with Venetoclax and the CDK7-targeting inhibitor THZ1 prevented the emergence and maintenance of Venetoclax resistance in models of mantle cell lymphoma and double-hit lymphoma. The patient samples assessment further proved the clinical relevance of this study, which can unveil the drug resistance mechanism in patient care in the future.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.
Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.
A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.